Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Anavex Life Sciences Corp

Healthcare US AVXL

2.645USD
-0.14(5.03%)

Last update at 2026-06-03T20:00:00Z

Day Range

2.612.75
LowHigh

52 Week Range

3.2510.45
LowHigh

Fundamentals

  • Previous Close 2.79
  • Market Cap710.59M
  • Volume1047519
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.51

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Income before tax -47.49800M -47.61943M -37.64107M -26.25781M -26.21280M
Minority interest - - - - -
Net income -47.49100M -47.97792M -37.90863M -26.28047M -26.29498M
Selling general administrative 12.04M 13.07M 9.02M 5.86M 6.85M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation - - - - -
Ebit - -54.39558M -41.92082M -30.75837M -28.75186M
Ebitda -47.49800M -50.08220M -41.67974M -31.06388M -28.88137M
Depreciation and amortization - 4.31M 0.24M -0.30551M -0.12952M
Non operating income net other - 2.42M 4.33M 4.65M 2.69M
Operating income -47.49800M -54.39558M -41.92082M -30.75837M -28.75186M
Other operating expenses 55.76M 50.99M 41.95M 30.94M 28.81M
Interest expense 0.96M 0.95M 4.04M 4.81M 2.67M
Tax provision 0.00700M 0.36M 0.27M 0.02M 0.08M
Interest income 6.52M 0.95M 0.03M 0.18M 0.21M
Net interest income 5.55M 0.95M 0.03M 0.18M 0.06M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.00700M 0.36M 0.27M 0.02M 0.08M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 55.76M 50.99M 41.95M 30.94M 28.81M
Cost of revenue - - - - -
Total other income expense net 2.68M 6.78M 4.28M 4.50M 2.54M
Discontinued operations - - - - -
Net income from continuing ops -47.50500M -47.97792M -37.90863M -26.28047M -26.29498M
Net income applicable to common shares - -47.97792M -37.90863M -26.28047M -26.29498M
Preferred stock and other adjustments - - - - -
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Total assets 154.39M 152.70M 161.62M 34.54M 25.33M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.65M 0.35M 0.37M 0.44M 3.14M
Total liab 12.53M 10.21M 10.80M 7.31M 5.04M
Total stockholder equity 141.85M 142.49M 150.82M 27.24M 20.29M
Deferred long term liab - 0.44M 0.44M - -
Other current liab 7.29M 5.94M 5.61M 3.32M 1.52M
Common stock 0.08M 0.08M 0.08M 0.06M 0.05M
Capital stock 0.08M 0.08M 0.08M 0.06M 0.05M
Retained earnings -293.06900M -245.56378M -197.58586M -159.67723M -133.39676M
Other liab - - - - -
Good will - - - - -
Other assets 3.36M 3546.74M 9.51M 5.29M -
Cash 151.02M 149.16M 152.11M 29.25M 22.19M
Cash and equivalents - - - - -
Total current liabilities 12.53M 10.21M 10.80M 7.31M 5.04M
Current deferred revenue 0.92M 0.44M 0.44M - -
Net debt -151.02400M -149.15786M -152.10774M -29.24902M -22.18563M
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity 434.84M 387.98M 348.33M 186.85M 153.63M
Property plant equipment - - - - -
Total current assets 154.39M 152.70M 161.62M 34.54M 25.33M
Long term investments - - - - -
Net tangible assets - 142.49M 150.82M 27.24M 20.29M
Short term investments - - - - -
Net receivables 2.71M 3.19M 9.14M 4.85M 2.64M
Long term debt - - - - -
Inventory - - - - -2.64275M
Accounts payable 4.32M 3.82M 4.74M 3.99M 3.52M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - 0.08M 0.08M 0.06M 0.05M
Preferred stock total equity - - - - -
Retained earnings total equity - -245.56378M -197.58586M -159.67723M -133.39676M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - 0.02M - 0.00000M
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 0.00000M 0.02M 0.00000M 0.00000M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Investments - - - - -
Change to liabilities - -0.91500M 1.19M 2.27M 1.27M
Total cashflows from investing activities - - - - -
Net borrowings - - - - -0.05000M
Total cash from financing activities 29.65M 21.29M 153.24M 28.35M 17.78M
Change to operating activities - 6.28M -1.90100M -0.34920M 0.62M
Net income -47.50500M -47.97792M -37.90863M -26.28047M -26.29498M
Change in cash 1.87M -2.94988M 122.86M 7.06M -0.74501M
Begin period cash flow 149.16M 152.11M 29.25M 22.19M 22.93M
End period cash flow 151.02M 149.16M 152.11M 29.25M 22.19M
Total cash from operating activities -27.78500M -24.23786M -30.38367M -21.28705M -18.52712M
Issuance of capital stock 27.88M 20.98M 153.22M 28.75M 17.83M
Depreciation - - - - -
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - -2.20660M -
Sale purchase of stock - 21.29M 153.24M 28.35M 17.83M
Other cashflows from financing activities 1.78M 0.30M 0.02M -0.40376M -0.05000M
Change to netincome - 18.38M 8.23M 4.88M 6.32M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -0.77239M
Cash flows other operating - 5.95M -3.75537M -2.14944M 0.95M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -2.94988M 122.86M 7.06M -0.74501M
Change in working capital 2.50M 5.36M -0.70644M 0.12M 1.30M
Stock based compensation 16.37M 18.38M 8.23M 4.88M 6.43M
Other non cash items 0.84M - 31.18M -6.83035M 0.04M
Free cash flow -27.78500M -24.23786M -30.38367M -21.28705M -18.52712M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
AVXL
Anavex Life Sciences Corp		 -0.14 5.03% 2.65 - - - 5.42 -5.5379
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Anavex Life Sciences Corp

630 5th Avenue, New York, NY, United States, 10111

Key Executives

Name Title Year Born
Dr. Christopher U. Missling M.B.A., M.S., Ph.D. Chairman, Pres, CEO & Sec. 1966
Ms. Sandra Boenisch CPA, CPA, CGA Principal Financial Officer & Treasurer 1981
Mr. Stephan Toutain Chief Operating Officer 1966
Dr. Walter E. Kaufmann M.D. Chief Scientific Officer NA
Dr. Emmanuel O. Fadiran RPh, Ph.D. Sr. VP of Regulatory Affairs NA
Clint Tomlinson VP of Corp. NA
Dr. Adebayo Laniyonu Ph.D. Sr. VP of Nonclinical Devel. NA
Dr. Edward R Hammond M.D., M.P.H., Ph.D. Chief Medical Officer NA
Dr. Christopher U. Missling M.B.A., M.S., Ph.D. President, CEO, Secretary & Director 1966
Ms. Sandra Boenisch CPA, CGA Principal Financial Officer & Treasurer 1981

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions